OSR Health (OSRH) Acquisitions (2025 - 2026)
OSR Health's (OSRH) quarterly Acquisitions came in at $135.71 in Q2 2026, up 100.65% year-over-year from $67.63 in Q2 2025, and up 101.26% quarter-over-quarter from -$10754.7 in Q1 2026.
Powered by 
Analysis
OSR Health (OSRH) Acquisitions (2025 - 2026) Analysis & Trends
OSR Health has disclosed Acquisitions across 2 years of filings, most recently posting $135.71 for Q2 2026.
- In Q2 2026, Acquisitions rose 100.65% year-over-year to $135.71; the TTM figure through Jun 2026 stood at -$15525.0 (changed N/A YoY), while the FY2025 annual figure was -$1.2 million, changed N/A from the prior year.
- Acquisitions came in at $135.71 for Q2 2026 at OSR Health, up from -$10754.7 in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $8175.0 in Q4 2025 to a low of -$1.2 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 11.21 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | OSR Health | 6.59 Mn | 4.94 Mn | 86,605.00 | 135.71 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 135.71 |
| Mar 31, 2026 | -10,754.71 |
| Dec 31, 2025 | 8,175.00 |
| Sep 30, 2025 | -13,081.00 |
| Jun 30, 2025 | -20,759.20 |
| Mar 31, 2025 | -1.20 Mn |